These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34855643)

  • 1. Worldwide and Regional Efficacy Estimates of First-line Helicobacter pylori Treatments: A Systematic Review and Network Meta-Analysis.
    Zamani M; Alizadeh-Tabari S; Zamani V; Shokri-Shirvani J; Derakhshan MH
    J Clin Gastroenterol; 2022 Feb; 56(2):114-124. PubMed ID: 34855643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis.
    Han Z; Li Y; Kong Q; Liu J; Wang J; Wan M; Lin M; Lin B; Zhang W; Ding Y; Wang S; Mu Y; Duan M; Zuo X; Li YQ
    Helicobacter; 2022 Dec; 27(6):e12930. PubMed ID: 36156332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of second-line regimens for
    Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
    BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
    Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
    Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis.
    Wang B; Lv ZF; Wang YH; Wang H; Liu XQ; Xie Y; Zhou XJ
    World J Gastroenterol; 2014 Oct; 20(40):14973-85. PubMed ID: 25356059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis.
    Li BZ; Threapleton DE; Wang JY; Xu JM; Yuan JQ; Zhang C; Li P; Ye QL; Guo B; Mao C; Ye DQ
    BMJ; 2015 Aug; 351():h4052. PubMed ID: 26290044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
    BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
    Nyssen OP; Vaira D; Pérez Aísa Á; Rodrigo L; Castro-Fernandez M; Jonaitis L; Tepes B; Vologzhanina L; Caldas M; Lanas A; Lucendo AJ; Bujanda L; Ortuño J; Barrio J; Huguet JM; Voynovan I; Lasala JP; Sarsenbaeva AS; Fernandez-Salazar L; Molina-Infante J; Jurecic NB; Areia M; Gasbarrini A; Kupčinskas J; Bordin D; Marcos-Pinto R; Lerang F; Leja M; Buzas GM; Niv Y; Rokkas T; Phull P; Smith S; Shvets O; Venerito M; Milivojevic V; Simsek I; Lamy V; Bytzer P; Boyanova L; Kunovský L; Beglinger C; Doulberis M; Marlicz W; Goldis A; Tonkić A; Capelle L; Puig I; Megraud F; Morain CO; Gisbert JP;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2243-2257. PubMed ID: 34954341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis.
    Rokkas T; Gisbert JP; Malfertheiner P; Niv Y; Gasbarrini A; Leja M; Megraud F; O'Morain C; Graham DY
    Gastroenterology; 2021 Aug; 161(2):495-507.e4. PubMed ID: 33839101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line rescue treatment of
    Lin TF; Hsu PI
    World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management.
    Tepes B; Brglez Jurecic N; Tepes K; Espada Sanchez M; Perez Nyssen O; O'Morain C; Mégraud F; Gisbert J
    Dig Dis; 2021; 39(4):318-324. PubMed ID: 33099549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002].
    Buzás GM; Józan J
    Orv Hetil; 2004 Oct; 145(40):2035-41. PubMed ID: 15559530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
    Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
    Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
    Li Y; Huang X; Yao L; Shi R; Zhang G
    Wien Klin Wochenschr; 2010 Jul; 122(13-14):413-22. PubMed ID: 20628905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.
    Nyssen OP; McNicholl AG; Megraud F; Savarino V; Oderda G; Fallone CA; Fischbach L; Bazzoli F; Gisbert JP
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD009034. PubMed ID: 27351542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line
    Yeo YH; Shiu SI; Ho HJ; Zou B; Lin JT; Wu MS; Liou JM; Wu CY;
    Gut; 2018 Jan; 67(1):20-27. PubMed ID: 27670375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.
    Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2011 Sep; 34(6):604-17. PubMed ID: 21745241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.